Business Context and Reporting Period
Company: Atai Life Sciences N.V. (ATAI)
Filing Type: Form 8-K (Current Report)
Date of Report: July 1, 2025
Reporting Period: Specific event date (July 1, 2025)
This filing reports the entry into a material definitive agreement for a private investment in public equity (PIPE) financing and the announcement of positive clinical trial data from portfolio company Beckley Psytech. The Company is an emerging growth company incorporated in the Netherlands.
Key Financial Metrics and Capital Structure
PIPE Financing Details:
- Aggregate Gross Proceeds: Approximately $50 million.
- Securities Issued:
- 18,264,840 Common Shares at $2.19 per share.
- Pre-funded warrants to purchase 4,566,210 Common Shares at an exercise price of $0.01 (purchase price of $2.18 per underlying share).
- Expected Closing: Third quarter of 2025, subject to customary conditions.
- Use of Proceeds: General corporate purposes, working capital, and advancing clinical development of product candidates.
Liquidity Outlook: The Company estimates that, upon consummation of the PIPE Financing, its cash, short-term securities, and public equity holdings will be sufficient to fund operating expenses into the second half of 2027.
Other Financial Data: This filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period. The Company is a clinical-stage biopharmaceutical entity.
Material Changes and Strategic Developments
1. PIPE Financing Agreement: On July 1, 2025, the Company entered into subscription agreements with PIPE Investors. Notable participants include Apeiron Investment Group Ltd. (the family office of Co-Founder and Chairman Christian Angermayer). The financing is not conditioned on the closing of the Beckley Psytech acquisition.
2. Beckley Psytech Acquisition Context: The Company previously agreed (June 2, 2025) to acquire the remaining shares of Beckley Psytech Limited by issuing 105,044,902 Common Shares. The PIPE proceeds will not be used to finance this acquisition.
3. Clinical Data Announcement (Beckley Psytech): Beckley Psytech announced positive topline findings from a Phase IIb blinded clinical study of BPL-003 (Mebufotenin benzoate) in 193 patients with treatment-resistant depression (TRD).
- Efficacy: Statistically significant reductions in MADRS scores observed as early as Day 2.
- 12 mg dose: Mean reduction of 11.1 at Day 29 (p=0.0038) vs. 5.8 in comparator.
- 8 mg dose: Mean reduction of 12.1 at Day 29 (p=0.0025) vs. 5.8 in comparator.
- Durability: Effects observed through Day 57.
- Safety: Generally well-tolerated; >99% of adverse events were mild or moderate. No drug-related serious adverse events or treatment-emergent suicidal intent/behavior reported.
- Next Steps: Beckley Psytech plans to select the 8 mg dose for Phase III studies.
Guidance, Risks, and Contingencies
Forward-Looking Statements: The Company provides estimates regarding cash runway (into H2 2027) and the timing of the PIPE closing (Q3 2025). These are based on assumptions that may prove incorrect.
Key Risks and Conditions:
- Closing Conditions: The PIPE Financing is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) regarding Christian Angermayer's investment.
- Termination Rights: Either the Company or PIPE Investors may terminate the agreements if the financing is not consummated by November 1, 2025.
- Capital Consumption: The Company may use available capital resources sooner than expected.
- Regulatory Approval: Future clinical development and commercialization depend on regulatory approvals which are not guaranteed.
Investor Verification Checklist
- Verify the final closing date of the $50 million PIPE Financing and confirmation of HSR Act clearance.
- Review the full text of the Subscription Agreements (Exhibits 10.1, 10.2, 10.3) for specific covenants and termination rights.
- Monitor the progress of the Beckley Psytech acquisition (SPA) and the filing of the Form S-4 Registration Statement.
- Confirm the selection of the 8 mg dose for Phase III trials and the timeline for regulatory engagement.
- Assess the Company's actual cash burn rate against the projected runway into the second half of 2027.